Free Newsletter
MIT computer model designs better therapies
Researchers at MIT have developed a computer model which they say can rev up the effectiveness of an antibody-based therapy. And it's not just a theory. They say that they have used the model to design a new form of cetuximab (Erbitux)--a therapy for colorectal cancer--that is 10 times better at binding to its target than the original molecule. The model reviews potential amino-acid substitutions, looking for ways to build a structure with greater binding properties. The scientists say that better protein modeling can also reduce the cost of developing the drugs.
"New and better methods for improving antibody development represent critical technologies for medicine and biotechnology," says MIT Professor Dane Wittrup.
- see this release from MIT
- here's a report on the new model
Related Articles:
Universities, public institutes lead biotech revolution. Report
Computer advances allow new methods of protein analysis. Report
Universities create cardiac data grid. Report
Comments
Post new comment
Paid Research Reports
- The Specialty Pharma Market Outlook: Key players, new company growth models and emerging opportunities
- Investigating Clinical Trial Costs: Comparative analysis of trial cost components in key geographies
- Clinical Trial Recruitment Strategies: Optimizing patient recruitment and retention in late stage clinical trials
- Pipeline Insight: Therapeutic Cancer Vaccines - Prospect of first approval set to reinvigorate interest from major companies
- Stakeholder Opinions: Vaccines in Emerging Markets (Asia) - Opportunities in China, India, South Korea and Taiwan
- Big Pharma Performance Before, During and Beyond the Global Recession




